Representative Jefferson Shreve (R-Indiana) recently sold shares of Vaxcyte, Inc. NASDAQ: PCVX. In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Vaxcyte stock on March 5th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025.
- Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025.
- Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025.
- Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025.
- Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025.
- Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025.
Vaxcyte Trading Up 5.3 %
Shares of NASDAQ:PCVX traded up $1.53 during midday trading on Friday, reaching $30.65. The company had a trading volume of 1,724,222 shares, compared to its average volume of 1,220,251. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06. The company's 50 day moving average price is $61.81 and its 200 day moving average price is $83.64. The stock has a market cap of $3.95 billion, a P/E ratio of -6.66 and a beta of 1.26.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. Research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have issued reports on PCVX. The Goldman Sachs Group decreased their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Finally, Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $136.50.
Check Out Our Latest Research Report on PCVX
Insider Buying and Selling at Vaxcyte
In related news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now owns 205,695 shares of the company's stock, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 32,000 shares of company stock worth $2,638,800 over the last 90 days. Corporate insiders own 3.10% of the company's stock.
Hedge Funds Weigh In On Vaxcyte
Several hedge funds and other institutional investors have recently made changes to their positions in PCVX. Diversified Trust Co purchased a new position in Vaxcyte in the fourth quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. grew its position in shares of Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after buying an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Vaxcyte by 53.7% during the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares in the last quarter. Principal Financial Group Inc. lifted its position in Vaxcyte by 186.2% in the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock valued at $6,022,000 after acquiring an additional 34,287 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Vaxcyte by 70.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after acquiring an additional 246,049 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
